Genetron Health Reports Second Quarter 2021 Unaudited Financial Results

8/24/2021

BEIJING, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the second quarter ended June 30, 2021.

Second Quarter and Recent Highlights

  • Recorded total revenue of RMB 140.5 million (US$21.8 million) for the second quarter 2021, representing a 38.1% increase over the same period of 2020.
  • Generated LDT segment revenue with year on year growth of 15.0% to RMB 87.1 million (US$13.5 million) for the second quarter 2021.
  • IVD revenue was RMB 43.8 million (US$6.8 million) for the second quarter 2021, representing 141.5% growth over the same period of 2020, due to increasing sales of Genetron S5 instrument and 8-gene Lung Cancer Assay (Tissue).
  • Development services grew 21.8% compared to a year ago, based on our increasing effort in providing services to biopharmaceutical partners.
  • Achieved gross margin of 67.2% for the second quarter 2021, compared to 63.1% in the same period of 2020, thanks to improvements in both LDT and IVD business lines.
  • Genetron established a IVD partnership with Shanghai Yikon Genomics Technology Co., Ltd., in which the partner will have exclusive rights of its S5 instrument in the area of reproductive health.
  • Recently, Seq-MRD for hematologic cancers has signed on a leading pharmaceutical MNC for use in their clinical trial.
  • AYVAKIT® companion diagnostic kit, developed in partnership with CStone Pharmaceuticals, has entered the priority review and approval process under the NMPA in China.
  • Received CE Mark for 8-gene Lung Cancer Assay (Tissue).
  • Established collaboration with Guizhou Province’s Dafang County authorities to use HCCscreenTM for high-risk liver cancer patients in the rural markets.
  • Genetron’s Beijing lab achieved full marks and was ranked first in NCCL’s External Quality Assessment of participating clinical laboratories in China, based on its NGS-based comprehensive genomic profiling for solid tumors, Onco Panscan.

“In the second quarter, we delivered strong revenues, along with improved gross margins. We were pleased to see continued sales momentum across all of our business lines,” remarked Mr. Sizhen Wang, co-founder and CEO of Genetron Health. “Over the past several weeks, the stricter COVID policies in China have impacted our business, which at present we believe is temporary. We are closely monitoring the evolving situation and remain focused on executing our strategy in geographies and segments that are less affected by the restrictions. Notwithstanding the near-term challenges, we also continue to execute on the pipeline front in the second half. We are moving along with our NMPA registrational trial preparation for HCCscreenTM, and we project to release CRC data for early screening later this year. Our efforts in MRD are also progressing – with the upcoming LDT launch of Seq-MRD in blood cancers in the clinical settings, as well as other ongoing studies in solid tumors. As we continue to focus on achieving the important milestones for the company, we also remain confident about the overall growth prospects of the precision oncology sector in China, thanks to continued government support and related policy tailwinds that aim at providing broader and better healthcare options for Chinese citizens.”

Second Quarter 2021 Unaudited Preliminary Financial Results

Total revenue for the second quarter 2021 increased by 38.1% to RMB140.5 million (US$21.8 million) from RMB101.7 million in the same period of 2020.

Diagnosis and monitoring revenue increased by 39.4% to RMB131.0 million (US$20.3 million) in the second quarter 2021 from RMB93.9 million in the same period of 2020.  The increase was driven by the growth in the revenue generated from the sale of IVD products.

  • Revenue generated from the provision of LDT services increased by 15.0% to RMB87.1 million (US$13.5 million) during the second quarter 2021 from RMB75.8 million in the same period of 2020. In the second quarter, sales of LDT services included sales of our early screening test, HCCscreen. LDT diagnostic tests sold in the second quarter 2021 totaled approximately 6,840 units.
     
  • Revenue generated from sales of IVD products increased by 141.5% to RMB43.8 million (US$6.8 million) in the second quarter 2021 from RMB18.1 million in the second quarter 2020, due to increasing sales of Genetron S5 instrument and 8-gene Lung Cancer Assay (Tissue).


 
      Contracted in-hospital partners
(as of the end of the period indicated)
      
 2Q203Q204Q20 

1Q21
 

2Q21
      
IVD In-hospital partners1820222328
      
 2Q203Q204Q201Q21 2Q21
      
Total in-hospital partners(1)3538404250
Note:
(1) The number of total in-hospital partners include both sales of LDT services and IVD products.
 
  

Revenue generated from development services increased by 21.8% to RMB9.5 million (US$1.5 million) in the second quarter 2021, from RMB7.8 million in the same period of 2020. Biopharmaceutical revenue growth increased significantly in the second quarter of 2021 compared to the same period of 2020.

Cost of revenue increased by 22.7% to RMB46.0 million (US$7.1 million) for the three months ended June 30, 2021, compared to RMB37.5 million in the same period of 2020.

Gross profit increased by 47.1% to RMB94.5 million (US$14.6 million) in the second quarter 2021 from RMB64.2 million in the same period of 2020. Gross margin improved to 67.2% for the second quarter 2021, compared to 63.1% in the same period of 2020, mainly due to higher gross margins for both LDT and IVD business lines.

Operating expenses increased by 65.8% to RMB194.6 million (US$30.1 million) for the three months ended June 30, 2021, from RMB117.4 million in the same period of 2020.

Selling expenses increased by 46.0% to RMB88.5 million (US$13.7 million) in the second quarter 2021 from RMB60.6 million in the same period of 2020. Selling expenses as a percentage of revenues was 63.0% in the second quarter 2021, compared to 59.6% in the same period of 2020. The increase was primarily due to higher marketing expense and higher employee compensation expenses. 

Administrative expenses increased by 95.6% to RMB54.6 million (US$8.5million) in the second quarter 2021 from RMB27.9 million in the same period of 2020. Administrative expenses as a percentage of revenues increased to 38.8% in the second quarter 2021 from 27.4% in the second quarter 2020. The increases were mainly due to more headcount, higher professional fees, and IT expenses.

Research and development expenses increased by 88.2% to RMB56.2 million (US$8.7 million) in the second quarter 2021 from RMB29.8 million in the same period of 2020. Research and development expenses as a percentage of revenues increased to 40.0% in the second quarter of 2021 from 29.3% in the same period of 2020. The increases were driven by higher R&D headcount and related expenses, as well as continued innovation efforts including product development and clinical trial activities.

As a result of the above, operating loss was RMB100.2 million (US$15.5 million) for the three months ended June 30, 2021, compared to RMB53.1 million for the three months ended June 30, 2020.

Net finance income increased to RMB8.0 million (US$1.2 million) in the second quarter 2021 from net finance costs of RMB0.6 million in the same period of 2020.  The increase was mainly driven by the foreign currency exchange gain.

Loss for the period was RMB92.1 million (US$14.3 million) for the three months ended June 30, 2021, compared to RMB2,832.4 million for the three months ended June 30, 2020. The Company recorded RMB2,778.6 million and nil in fair value loss of financial instruments with preferred rights for the three months ended June 30, 2020 and 2021, respectively.

Non-IFRS loss for the period, defined as loss for the period excluding share-based compensation expenses, fair value change and other loss of financial instruments with preferred rights, was RMB79.6 million (US$12.3 million) for the three months ended June 30, 2021, compared to RMB43.9 million for the three months ended June 30, 2020. Please refer to the section in this press release titled "Non-IFRS Financial Measures" for details.

Basic loss per ordinary share attributable to ordinary shareholders of the Company was RMB0.20 (US$0.03) for the second quarter of 2021, compared with a basic loss per share attributable to ordinary shareholders of the Company of RMB17.04 for the same period of 2020. Excluding share-based compensation expenses, fair value change of financial instruments with preferred rights and other loss of financial instruments with preferred rights, non-IFRS basic loss per share attributable to ordinary shareholders of the Company was RMB0.17 (US$0.03) for the second quarter of 2021, compared with non-IFRS basic loss per share attributable to ordinary shareholders of the Company of RMB0.26 for the same period of 2020. Diluted loss per share attributable to ordinary shareholders of the Company is equivalent to basic loss per share attributable to ordinary shareholders of the Company. Each ADS represents of five ordinary shares, par value US$0.00002 per share. Please refer to the section in this press release titled "Non-IFRS Financial Measures" for details.

As of June 30, 2021, our cash and cash equivalents, restricted cash and current financial assets at fair value through profit or loss were RMB1,214.0 million (US$188.0 million), compared to RMB1,516.1 million as of December 31, 2020. The total decrease was mainly used for operating activities.

2021 Financial Guidance

At this time, we expect the current COVID-related restrictions to be temporary, and are maintaining our 2021 expected revenue range of RMB615 million to RMB625 million. However, if the current environment sustains or worsens, the Company expects to reassess its financial projections and would provide appropriate updates to the market at that time.

Conference Call

A conference call and webcast to discuss the results will be held at 8:30 a.m. U.S. Eastern Time on August 24, 2021 (or at 8:30 pm Beijing Time on August 24, 2021). Interested parties may listen to the conference call by dialing numbers below:

United States:+1-845-675-0437
China Domestic:400-620-8038
Hong Kong:  +852-3018-6771
International: +65-6713-5090
Conference ID:7494097

Participants are encouraged to dial into the call at least 15 minutes in advance due to high call volumes.

A replay will be accessible through August 31, 2021 by dialing the following numbers:

United States:+1-855-452-5696
International:+61-2-8199-0299
Conference ID:7494097

A simultaneous webcast of the conference call will be available on the "News and Presentations" page of the Investors section of the Company's website. A replay of the webcast will be available for 30 days following the event. For more information, please visit ir.genetronhealth.com.

Exchange Rate Information

All translations made in the financial statements or elsewhere in this press release made from RMB into United States dollars (“US$”) are solely for convenience and calculated at the rate of US$1.00=RMB 6.4566, representing the exchange rate as of June 30, 2021, set forth in the H.10 statistical release of the U.S. Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate, or at any other rate, on June 30, 2021.

Non-IFRS Financial Measures

The Company uses non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period, which are non-IFRS financial measures, in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company help identify underlying trends in the Company's business that could otherwise be distorted by the effect of certain expenses that the Company includes in its loss for the year/period. The Company believes that non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period provide useful information about its results of operations, enhances the overall understanding of its past performance and future prospects and allows for greater visibility with respect to key metrics used by its management in its financial and operational decision-making.

Non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period should not be considered in isolation or construed as an alternative to operating profit, loss for the year/period or any other measure of performance or as an indicator of its operating performance. Investors are encouraged to review non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period and the reconciliation to its most directly comparable IFRS measures. Non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to the Company's data. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

Non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period represent loss for the year/period excluding share-based compensation expenses, fair value change of financial instruments with preferred rights and other loss of financial instruments with preferred rights (if applicable).

Please see the “Unaudited Non-IFRS Financial Measures” included in this press release for a full reconciliation of non-IFRS loss for the year/period to loss for the year/period and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period to loss per share attributable to ordinary shareholders of the Company for the year/period.

About Genetron Holdings Limited

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contact
US:
Hoki Luk
Head of Investor Relations
Email: hoki.luk@genetronhealth.com
Phone: +1 (408) 891-9255

David Deuchler, CFA
Managing Director | Gilmartin Group
ir@genetronhealth.com

Media Relations Contact
Yanrong Zhao
Genetron Health
yanrong.zhao@genetronhealth.com

Edmond Lococo
ICR
Edmond.Lococo@icrinc.com
Mobile: +86 138-1079-1408
genetron.pr@icrinc.com


GENETRON HOLDINGS LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS

          For the three months ended  For the six months ended
 June 30, 2020  June 30, 2021     June 30,2020  June 30, 2021    
 RMB’000  RMB’000  US$’000  RMB’000  RMB’000  US$’000 
Revenue 101,735  140,485  21,758  178,578  232,546  36,017 
Cost of revenue(37,512) (46,021) (7,128) (72,117) (83,533) (12,938)
                  
Gross profit64,223  94,464  14,630  106,461  149,013  23,079 
                  
Selling expenses(60,618) (88,516) (13,709) (114,442) (148,187) (22,951)
Administrative expenses(27,906) (54,577) (8,453) (49,529) (99,180) (15,361)
Research and development expenses(29,845) (56,162) (8,698) (57,474) (106,136) (16,438)
Net impairment losses on
financial and contract assets
(267) (3,474) (538) (990) (13,304) (2,061)
Other income and gains/(losses) - net1,270  8,081  1,252  (4,332) 8,611  1,335 
                  
Operating expenses(117,366) (194,648) (30,146) (226,767) (358,196) (55,476)
                  
Operating loss(53,143) (100,184) (15,516) (120,306) (209,183) (32,397)
                  
Finance income198  9,447  1,463  228  5,179  802 
Finance costs(827) (1,409) (218) (4,375) (3,180) (493)
                  
Finance (costs)/income - net(629) 8,038  1,245  (4,147) 1,999  309 
Fair value loss of financial instruments with preferred rights(2,778,591) -  -  (2,823,370) -  - 
Loss before
income tax
(2,832,363) (92,146) (14,271) (2,947,823) (207,184) (32,088)
Income tax expense-  -  -  -  -  - 
                  
Loss for the period(2,832,363) (92,146) (14,271) (2,947,823) (207,184) (32,088)
                  
Loss attributable to:                 
Owners of the Company(2,832,363) (91,820) (14,221) (2,947,823) (204,574) (31,684)
Non-controlling interests-  (326) (50) -  (2,610) (404)
 (2,832,363) (92,146) (14,271) (2,947,823) (207,184) (32,088)
                  
Loss per share attributable to ordinary shareholders of the Company RMB  RMB  USD  RMB  RMB  USD 
-Basic and diluted(17.04) (0.20) (0.03) (20.25) (0.45) (0.07)
Loss per ADS attributable to ordinary shareholders of the Company                 
-Basic and diluted(85.22) (1.00) (0.15) (101.23) (2.23) (0.35)
                  
Shares used in loss per share attributable to ordinary shareholders of the Company computation:                 
-Basic and diluted166,179,400  459,903,803  459,903,803  145,604,263  458,999,227  458,999,227 
ADS used in loss per ADS attributable to ordinary shareholders of the Company computation:                 
-Basic and diluted33,235,880  91,980,761  91,980,761  29,120,853  91,799,845  91,799,845 


GENETRON HOLDINGS LIMITED

UNAUDITED NON-IFRS FINANCIAL MEASURE

 For the three months endedFor the six months ended
 
 June 30, 2020June 30, 2021June 30, 2020June 30, 2021
 RMB’000RMB’000USD’000RMB’000RMB’000USD’000
       
       
Loss for the period(2,832,363) (92,146) (14,271) (2,947,823) (207,184) (32,088)
Adjustments:      
Share-based
compensation
9,903  12,504  1,937  14,954  21,754  3,369 

Fair value loss of financial instruments with preferred rights
2,778,591  -  -  2,823,370  -  - 
Non-IFRS  Loss(43,869) (79,642) (12,334) (109,499) (185,430) (28,719)
                  
       
Attributable to:      
Owners of the Company(43,869) (79,316) (12,284) (109,499) (182,820) (28,315)
Non-controlling interests-  (326) (50) -  (2,610) (404)
 (43,869) (79,642) (12,334) (109,499) (185,430) (28,719)
                  
       
Non-IFRS loss per share attributable to ordinary shareholders of the CompanyRMBRMBUSDRMBRMBUSD
-Basic and diluted(0.26) (0.17) (0.03) (0.75) (0.40) (0.06)
                  
       
Non-IFRS loss per
ADS (5 ordinary shares equal to 1 ADS) attributable to ordinary shareholders of the Company
      
-Basic and diluted(1.32) (0.86) (0.13) (3.76) (1.99) (0.31)
                   
Shares used in non-IFRS loss per share attributable to ordinary shareholders of the Company computation:                  
-Basic and diluted166,179,400  459,903,803  459,903,803  145,604,263  458,999,227  458,999,227 
       
ADS used in non-IFRS loss per ADS attributable to ordinary shareholders of the Company computation:      
-Basic and diluted33,235,880  91,980,761  91,980,761  29,120,853  91,799,845  91,799,845 

                                                                                                       
GENETRON HOLDINGS LIMITED
UNAUDITED REVENUE AND SEGMENT INFORMATION

       
        
 Diagnosis and monitoring

 Diagnosis and monitoring

 Development services Total
- provision of LDT services
- sale of IVD products
 
RMB’000
 
RMB’000
 
RMB’000
 
RMB’000
        
Three months ended June 30, 2020      
Revenue75,772 18,145 7,818  101,735
Segment profit53,094 10,040 1,089  64,223
        
Three months ended June 30, 2021      
Revenue87,138 43,827 9,520  140,485
Segment profit61,890 31,312 1,262  94,464
        
Six months ended June 30, 2020      
Revenue123,348 37,358 17,872  178,578
Segment profit/(loss)81,749 25,388 (676) 106,461
        
Six months ended June 30, 2021      
Revenue158,966 59,093 14,487  232,546
Segment profit110,701 36,534 1,778  149,013


GENETRON HOLDINGS LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

  As at December 31,2020 As at June 30,2021
  RMB’000 RMB’000 US$’000
ASSETS      
Non-current assets      
Property, plant and equipment 76,891 76,746 11,886
Right-of-use assets 59,706 55,583 8,609
Intangible assets 12,265 15,284 2,367
Financial assets at fair value through profit or loss 19,609 36,334 5,628
Prepayments 15,362 23,418 3,627
       
Total non-current assets 183,833 207,365 32,117
       
Current assets      
Inventories 24,971 32,978 5,108
Contract assets 1,112 2,188 339
Other current assets 36,500 31,255 4,841
Trade receivables 164,592 211,898 32,819
Other receivables and prepayments 42,420 46,835 7,254
Amounts due from related parties 214 225 35
Financial assets at fair value through profit or loss140,294 142,194 22,023
Derivative financial instruments196 745 115
Restricted cash- 5,000 774
Cash and cash equivalents 1,375,766 1,066,815 165,229
       
Total current assets 1,786,065 1,540,133 238,537
       
Total assets 1,969,898 1,747,498 270,654
       


GENETRON HOLDINGS LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS CONTINUED                                                                                                          

  As at December 31,2020As at June 30,2021
  RMB’000RMB’000US$’000
     
LIABILITIES    
Non-current liabilities    
Borrowings 5,493  1,709  265 
Lease liabilities 43,016  38,627  5,983 
Other non-current liabilities -  8,096  1,254 
          
     
Total non-current liabilities 48,509  48,432  7,502 
          
     
     
Current liabilities    
Trade payables 34,071  36,172  5,602 
Contract liabilities 8,417  9,719  1,505 
Other payables and accruals 111,164  107,742  16,688 
Amounts due to related parties 24  513  79 
Borrowings 58,583  27,903  4,322 
Lease liabilities 16,585  19,087  2,956 
Derivative financial instruments -  4,219  653 
          
     
Total current liabilities 228,844  205,355  31,805 
          
     
Total liabilities 277,353  253,787  39,307 
          
     
Net assets 1,692,545  1,493,711  231,347 
          
     
     
     
SHAREHOLDERS’ EQUITY    
Equity attributable to owners of the Company  
Share capital 59  59  9 
Share premium 6,657,562  6,680,307  1,034,648 
Other reserves (24,701) (49,917) (7,731)
Accumulated losses (4,940,375) (5,144,949) (796,851)
          
     
  1,692,545  1,485,500  230,075 
          
     
Non-controlling interests -  8,211  1,272 
          
     
Total shareholders’ equity1,692,545  1,493,711  231,347 
         
     

Print Page
Email Alerts
RSS
Contact IR
Search